Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: September 03, 2026
Novel murine models of hematopoietic-endothelial crosstalk in JAK2V617F-associated cardiovascular disease.
Journal: The American journal of pathology
Published: May 08, 2026
Targeting TPO/MPL Signaling to Mitigate JAK2V617F-driven Cardiac Microvascular Disease.
Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026
When Less Is Enough: Lowest Effective Dose in Clinical Practice.
Journal: The American journal of medicine
Published: March 15, 2026
Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.
Journal: Haematologica
Published: August 13, 2025
The Immune-Modulatory Function of Megakaryocytes in the Hematopoietic Niche of Myeloproliferative Neoplasms.
Journal: bioRxiv : the preprint server for biology
Published: April 16, 2025
Dexrazoxane makes doxorubicin-induced heart failure a rare event in sarcoma patients receiving high cumulative doses.
Journal: Cardio-oncology (London, England)
Published: December 13, 2024
Body Surface Area in Obesity: Clinical Challenges and Call for Improvements.
Journal: Annals of internal medicine
Published: November 11, 2024
Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: July 11, 2024
Preventing Anthracycline-Associated Heart Failure: What Is the Role of Dexrazoxane?: JACC: CardioOncology Controversies in Cardio-Oncology.
Journal: JACC. CardioOncology
Published: May 22, 2024
Trastuzumab-Induced Cardiotoxicity: When and How Much Should We Worry?
Journal: JCO oncology practice
Published: April 25, 2024
Last Updated: 09/26/2026